Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 09, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 20, 2025
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 19, 2025
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).
Journal: ESMO open
Published: December 18, 2024
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.
Journal: The New England journal of medicine
Published: October 30, 2024
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 05, 2024
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 22, 2024
Ancestry-associated co-alteration landscape of KRAS and EGFR-altered non-squamous NSCLC.
Journal: NPJ precision oncology
Published: January 12, 2024
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
Journal: Nature medicine
Published: October 18, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
Journal: The New England journal of medicine
Published: August 23, 2023
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.
Journal: NPJ precision oncology
Published: May 05, 2022
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 23, 2018
Last Updated: 09/26/2026